BECN1 and neoplasm: Assessment of patients survival revealed that decreased expression of Beclin 1 was closely associated with poor disease-specific survival (P<0.0001, Figure 1F), and the mean survival time for patients with tumor having low-expressed Beclin 1 was 57.8 months compared to 110.2 months for patients with tumor having highly-expressed Beclin 1 (Table 2).